ABC has assembled a Board of Scientific Advisors providing unparalleled expertise, strategic support, and deep networks
The ABC Board is a carefully curated, well rounded group of preeminent industry experts in their field leveraging decades of ground breaking experience and success toward sound strategic direction and insight for ABC and the clients we serve.
They are assembled as the backstop of “Smart Strategy” covering all bases with regard to the critical areas of consideration within drug development - Business Development, Regulatory, Clinical, Clinical Operations, CMC, Project leadership & Management, Patient Advocacy and Talent Acquisition.
The Board includes alumni from venerated firms such as Allergan, BMS, Biogen, Genzyme, Sanofi, Merck, bluebird bio, Sarepta, Kite Pharma and Laidlaw with key leadership roles - Head of R&D, Chief Regulatory Officer, Head of Clinical Affairs, CMO, Board member and Founder and Chief of a premier biotech search firm.
ABC Scientific Advisory Board
-
Sean O'Bryan
Founder and Chief Consultant, Accelerated Biologics Consulting. L.L.C
Over an impressive 30-year career, establishing himself as a preeminent expert in the field of biotech Regulatory Affairs, Sean acts as Chief Regulatory Officer and often times project lead guiding all aspects of R&D program development. He has led and advanced multiple international biotechnology companies through preclinical and clinical phase through BLA approval including; Biogen, Genzyme/Sanofi, Freeline, Axovant, Lysogene, and bluebird bio , consistently implementing groundbreaking initiatives including landmark rare disease adaptive design trials, new pathways for xenotransplant, and innovative regulatory CMC strategy and new market frameworks (e.g. cell therapy trial approval/implementation process in China). Sean is in excellent standing and well respected with the CDRH, CBER, EMA, MHRA and Health Canada authorities.
-
Dr. Gavin Corcoran
Gavin Corcoran is the Chief Medical Officer at TrialSpark
Dr Corcoran oversees the scientific and medical input to the drug development process from the business development efforts to identify new products through the medical oversight of clinical trials to the regulatory filings and approval of the products.
Prior to joining TrialSpark, he held several senior leadership roles including the CMO at Allergan and Stiefel where he provided oversight of the regulatory approval of many products across a number of therapeutic areas.
His academic training is in infection diseases and he was on the faculty of the University of Texas Health Sciences Center in San Antonio, TX prior to joining the pharmaceutical industry over 20 years ago.
-
Dr. Paul Korner, M.D.
Chief Medical Officer of Agile Therapeutics, Inc. and active consultant for cell and gene therapy companies
Dr. Paul Korner is physician executive with over 22 years of pharmaceutical/biotech industry experience, serving in senior R & D leadership position for Ferring Pharmaceuticals, Ardelyx Inc., Sarepta Therapeutics, Axovant Gene Therapies.
He is currently the Chief Medical Officer of Agile Therapeutics, Inc. He has been responsible for multiple INDs/CTAs and more than 50 clinical trials (phase 1-4), leading to marketing authorization/approvals of 10 products including VYONDYS 53® (golodirsen), NOCDURNA® (desmopressin), PREPOPIK® (sodium picosulfate), EUFLEXXA® (1% sodium hyaluronate), and YAZ® (EE/drospiranone). While serving as SVP Clinical & Medical Affairs at Axovant Gene Therapies, he advanced two gene therapy programs into IND and BLA enabling clinical trials for GM1 and GM2 gangliosidosis.
Under consultancy, he has been part of Laidlaw Venture Partners since 2018 providing strategic and operational scientific/clinical guidance to portfolio companies.
-
Sarah J Fritchley. PhD
Founder and Chief Consultant, Fritchley Clinical Development Ltd.
Sarah’s 20- year career in clinical development has spanned all development phases impacting various therapeutic areas. She has worked in micro start up through mid-sized global biotechs and has successfully directed multiple programs within the CRO sector.
Companies include Adprotech, Genzyme/Sanofi, Arakis/Sosei-Heptares, Covance, Camallergy, and most recently Exvastat Chief Development Officer.
Sarah is an agile leader in clinical development, with an aptitude for program management and communication excellence, directing large successful teams.
A pharmacologist by training and then with an immunology PhD, Sarah spent some years in pre-clinical research before finding her passion for clinical development and program management..
-
Matthew Tong
Founder and CEO, Intelisci, L.L.C.
Matt has held senior level roles in international people solution organizations holding responsibility for P&L, strategic direction, and tactical deployment of resources. Often as the founding employee in new regions, Matt has been a champion for growth, innovation, and customer service. His efforts have helped his previous companies attract and develop talented people, build ‘fit for purpose’ functional teams, achieve market penetration and foster strong relationships based on a reputation for excellent service.
As an effective FTE and consultant search professional and business builder, Matt brings a broad overview of market trends, business opportunity and commercial perspective to ABC.